Compare mazdutide vs semaglutide: how their mechanisms differ, FDA approval status, weight loss results, side effects, and what US patients should know.
Mazdutide and semaglutide are both injectable medications that target the GLP-1 receptor, but mazdutide also activates the glucagon receptor while semaglutide does not. Semaglutide is FDA-approved in the United States for type 2 diabetes and chronic weight management, whereas mazdutide is still investigational and has not been approved by the FDA for any human use. This means US patients can only get semaglutide with a prescription, while mazdutide is available only through clinical trials.
How Mazdutide and Semaglutide Work
Semaglutide is a GLP-1 receptor agonist. It mimics the natural hormone GLP-1, which slows stomach emptying, reduces appetite, and improves blood sugar control.
Mazdutide is a dual GLP-1 and glucagon receptor agonist. The GLP-1 part works like semaglutide, while the glucagon part may increase energy expenditure and fat burning. This dual action is being studied for its potential to produce greater weight loss and improve liver fat.
Mazdutide is being developed by Innovent Biologics. It is not a peptide that people can buy online; it is an investigational prescription drug. People searching for mazdutide peptide dosage should understand that no safe or approved dosage exists for self-administration outside of a clinical trial.
FDA Approval and Availability in the US
Semaglutide is approved under several brand names. Ozempic and Rybelsus are approved for type 2 diabetes, and Wegovy is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Mazdutide is not FDA-approved. As of 2025, it is under regulatory review in China for weight management, but it is not available in the US outside of clinical trials.
Because of this difference, US doctors cannot prescribe mazdutide. Patients who want semaglutide need a prescription and should be monitored by a healthcare professional.
Mazdutide vs Semaglutide: Side-by-Side Comparison
| Feature | Mazdutide | Semaglutide |
|---|---|---|
| Drug class | Dual GLP-1/glucagon receptor agonist | GLP-1 receptor agonist |
| FDA approval | Not approved | Approved for T2D and weight management |
| Administration | Weekly injection (investigational) | Weekly injection or daily oral (Rybelsus) |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
| Weight loss in trials | About 10% to 15% in Phase 2 trials | About 15% at 68 weeks in STEP 1 |
| Availability in US | Clinical trials only | Prescription only |
Weight Loss Results from Clinical Trials
In the STEP 1 trial, semaglutide 2.4 mg produced an average weight loss of about 15% over 68 weeks in adults with obesity. This result made semaglutide a benchmark for injectable weight loss medications.
Mazdutide has shown promising results in Phase 2 trials. Different doses produced weight loss in the range of 10% to 15% over 24 to 48 weeks, with higher doses generally leading to greater weight loss.
These numbers should not be compared directly. The trials enrolled different populations, used different doses, and lasted different lengths of time. There has been no head-to-head trial of mazdutide versus semaglutide.
Safety, Side Effects, and Regulatory Status
Both drugs can cause gastrointestinal side effects. The most common are nausea, vomiting, diarrhea, and constipation. These effects often improve as the body adjusts, but they can be severe in some people.
Semaglutide carries a boxed warning for thyroid C-cell tumors. The long-term safety profile of mazdutide is still unknown because it is investigational.
No one should use mazdutide or semaglutide without a prescription and medical oversight. People who are pregnant, breastfeeding, or have a history of pancreatitis or gallbladder disease should talk to a doctor before considering these medications.
Some researchers discuss mazdutide with tirzepatide as a possible future combination, but no clinical trial has tested this pairing. Combining weight loss drugs is not recommended outside of a research setting.
If you are looking for the best oral peptides for muscle growth and fat loss, note that mazdutide and semaglutide are not oral peptides. They are injectable prescription drugs with different legal and safety considerations.
Research-Grade Peptides and Legal Status
Mazdutide and semaglutide are sometimes discussed alongside research peptides sold online. However, mazdutide is not legally available for human use in the US, and semaglutide requires a prescription.
Websites such as Toppeptides may sell peptides labeled for research purposes only. These products are not FDA-approved for human consumption, and their purity and safety are not guaranteed.
Similarly, bp157 peptide is often sold as a research chemical, but it is not approved for human use. Buying any of these substances online for personal use carries legal and health risks.
Key Takeaways
- Mazdutide is not FDA-approved for human use in the United States.
- Semaglutide is FDA-approved for type 2 diabetes and chronic weight management.
- Mazdutide is a dual GLP-1/glucagon agonist, while semaglutide is a GLP-1 agonist.
- No head-to-head trial has directly compared mazdutide and semaglutide.
- Both drugs can cause gastrointestinal side effects and require medical supervision.
- Anyone considering weight loss medication should consult a licensed healthcare professional.
Frequently Asked Questions
Is mazdutide FDA approved?
No, mazdutide is not FDA-approved for any human use in the United States. It is an investigational drug that is being studied in clinical trials for obesity and type 2 diabetes. US patients cannot get a prescription for mazdutide.
How does mazdutide compare to semaglutide for weight loss?
There is no head-to-head trial comparing mazdutide and semaglutide. In separate trials, semaglutide 2.4 mg produced about 15% weight loss at 68 weeks, while mazdutide produced about 10% to 15% weight loss in Phase 2 trials. These numbers cannot be directly compared because the studies were different.
Can I take mazdutide with semaglutide or tirzepatide?
No, there is no research on combining mazdutide with semaglutide or tirzepatide. Combining GLP-1 drugs could increase the risk of severe gastrointestinal side effects. Only a healthcare professional should manage weight loss medications, and combinations should only be used in a clinical trial.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.